Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients
Open accessPublished version of a preprint
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of germline pathogenic mutations in a comprehensive panel of cancer predisposition genes is not well-defined for patients with pancreatic ductal adenocarcinoma (PDAC). To estimate the frequency of mutations in a panel of 22 cancer predisposition genes, 96 patients unselected for a family history of cancer who were recruited to the Mayo Clinic Pancreatic Cancer patient registry over a 12-month period were screened by next-generation sequencing. Fourteen pathogenic mutations in 13 patients (13.5%) were identified in eight genes: four in ATM, two in BRCA2, CHEK2, and MSH6, and one in BARD1, BRCA1, FANCM, and NBN. These included nine mutations (9.4%) in established pancreatic cancer genes. Three mutations were found in patients with a first-degree relative with PDAC, and 10 mutations were found in patients with first- or second-degree relatives with breast, pancreas, colorectal, ovarian, or endometrial cancers. These results suggest that a substantial proportion of patients with PDAC carry germline mutations in predisposition genes associated with other cancers and that a better understanding of pancreatic cancer risk will depend on evaluation of families with broad constellations of tumors. These findings highlight the need for recommendations governing germline gene-panel testing of patients with pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our data show, for the first time, that predisposition to MPM is very heterogeneous, similar to that reported for pancreatic cancer and other cancer types [17,18,38].”
From Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma (2017) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 2×
“Coverage was evaluated by Integrative Genomics Viewer (IGV) (18).”
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · cited 1×
“In the United States, pancreatic cancer is the fourth most common cause of cancer death (2).”
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., & Domellof, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,757 · cited 1×
“3, 4), Lynch syndrome (5, 6), familial adenomatous polyposis (7), familial atypical multiple mole melanoma syndrome (8), hereditary pancreatitis (9), Peutz–Jeghers syndrome (10), and Li–Fraumeni syndrome (11).”
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Very high risk of cancer in familial Peutz–Jeghers syndrome
Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., Cruz–Correa, M., & Offerhaus, J. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.20228 · Cited by 1,445 · cited 1×
“3, 4), Lynch syndrome (5, 6), familial adenomatous polyposis (7), familial atypical multiple mole melanoma syndrome (8), hereditary pancreatitis (9), Peutz–Jeghers syndrome (10), and Li–Fraumeni syndrome (11).”
Self-citationRisch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680 · cited 1×
“Few studies have implicated BRCA1 in pancreatic cancer (3, 4).”
Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds with p16INK4Mutations
Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., Zametkin, D. P., Fontaine, L. S., Organic, S. M., Dracopoli, N. C., Clark, W. H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331504 · Cited by 622 · cited 1×
“3, 4), Lynch syndrome (5, 6), familial adenomatous polyposis (7), familial atypical multiple mole melanoma syndrome (8), hereditary pancreatitis (9), Peutz–Jeghers syndrome (10), and Li–Fraumeni syndrome (11).”
Risk of Pancreatic Cancer in Families With Lynch Syndrome
Kastrinos, F. (2009) · JAMA · doi:10.1001/jama.2009.1529 · Cited by 544
Cited by
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
“In a sample of 96 patients with pancreatic cancer, 2 mutations were found in theMSH6MMR gene.(93) Microsatellite instability (MSI) is also a prognostic factor for survival in many cancers, notably for colon cancer although rare in pancreatic adenocarcinoma.”
BackgroundInfluentialHu, C., Hart, S. N., Polley, E. C., Gnanaolivu, R., Shimelis, H., Lee, K. Y., Lilyquist, J., Na, J., Moore, R., Antwi, S. O., et al. (2018) · JAMA · doi:10.1001/jama.2018.6228 · Cited by 577
“Epidemiologic studieshaveshownthat 10%to20%ofpancreatic cancers are associatedwith an inherited component.(5) Deleterious mutations in BRCA2 (RefSeq NM_000059.”
Self-citationDaly, M. B., Pilarski, R., Yurgelun, M. B., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Garber, J. E., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0017 · Cited by 505
Diabetes, pancreatogenic diabetes, and pancreatic cancer
Andersen, D. K., Korc, M., Petersen, G. M., Eibl, G., Li, D., Rickels, M. R., Chari, S. T., & Abbruzzese, J. L. (2017) · Diabetes · doi:10.2337/db16-1477 · Cited by 516
“More recently, patients with apparent sporadic PDAC have been reported to carry germline mutations in major genes as well (21); this is likely to change our current paradigm for risk assessment.”
BackgroundSelf-citationDeleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
Shindo, K., Yu, J., Suenaga, M., Fesharakizadeh, S., Cho, C., Macgregor-Das, A., Siddiqui, A., Witmer, P. D., Tamura, K., Song, T. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.3502 · Cited by 458
Metadata
- Authors
- Hu, C., Hart, S. N., Bamlet, W. R., Moore, R. M., Nandakumar, K., Eckloff, B. W., Lee, Y. K., Petersen, G. M., McWilliams, R. R., & Couch, F. J.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Couch, Fergus J.
- ORCID
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2016-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 207-211
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- PMC
- PMC4754121
- OpenAlex
- W1844119416
- Cited by
- 137
- References
- 26
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 13 · 2021: 18 · 2020: 16 · 2019: 18 · 2018: 17 · 2017: 17 · 2016: 12
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA116167, R01CA116167, P20CA102701, P50CA102701, U01CA116167, P30CA15083, P30CA015083)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- pancreatic ductal adenocarcinoma, germline pathogenic variants, cancer susceptibility genes, hereditary cancer, ATM, BRCA2, CHEK2, MSH6, BARD1, BRCA1, FANCM, niobium nitride, cancer risk, family history of cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Genetic Testing, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Prospective Studies, Biomarkers, Tumor, Prevalence, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. https://app.cochat.ai/papers/10.1158/1055-9965.epi-15-0455
- The paper
- Hu, C., Hart, S. N., Bamlet, W. R., Moore, R. M., Nandakumar, K., Eckloff, B. W., Lee, Y. K., Petersen, G. M., McWilliams, R. R., & Couch, F. J. (2016). Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-15-0455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.